Breakthroughs in mRNA Analysis by Size Exclusion Chromatography

Breakthroughs in mRNA Analysis by Size Exclusion Chromatography
17/10/25

The Key Points

  1. mRNA Therapeutics:

    • mRNA-based therapies are gaining significant attention for their potential to treat a wide range of diseases by delivering genetic information that can instruct cells to produce therapeutic proteins.

    • Exogenous mRNA is delivered to cells, where it’s translated into proteins, which could be used in immunotherapy, gene editing, or protein replacement therapies.

  2. Manufacturing:

    • The in vitro transcription (IVT) process, which synthesizes the mRNA, is a robust, scalable, and cost-effective method. After synthesis, mRNA is purified using liquid chromatography and ultrafiltration.

    • Delivery systems, like AAVs (Adeno-Associated Viruses) and LNPs (Lipid Nanoparticles), are critical for ensuring that mRNA reaches the target cells and is protected from degradation.

  3. Quality Control:

    • The complexity of mRNA therapeutics makes quality control paramount. SEC (Size Exclusion Chromatography) is highlighted as a key method for assessing drug purity and ensuring that the final product is safe, effective, and consistent.

    • SEC helps analyze both the IVT mRNA (drug substance) and the encapsulated mRNA (drug product) by providing insights into molecular mass, impurities, aggregates, and particle size distribution.

    • Proper column selection for SEC is critical to separate mRNA from aggregates or impurities, with the choice depending on the sample's size and characteristics. For example, AAVs require columns with pore sizes of ~550–700 Å, while mRNA may need a broader pore size (up to 1000 Å) for optimal separation.

  4. Advanced SEC Applications:

    • For applications like polyA tail mapping, SEC with smaller pore sizes (~200 Å) is used to separate the polyA tail from the rest of the mRNA sequence. This provides valuable information about the length of the polyA tail, which can impact mRNA stability and translation efficiency.

    • This level of analysis is particularly useful for peptide mapping in LC-MS/MS techniques.

Further Discussion:

  • Delivery System Innovations: It’s interesting to note that both AAVs and LNPs play a critical role, but they come with different challenges. AAVs are viral vectors that can be immunogenic and have size limitations, while LNPs, though more flexible, still face challenges with efficient delivery and stability. As both these systems evolve, the refinement of these technologies will likely be key in improving the efficacy of mRNA therapeutics.

  • Analytical Methodology: The focus on SEC as an analytical tool is crucial. For ensuring the quality of mRNA therapeutics, it’s essential to understand how well the mRNA and its delivery system perform under real-world conditions. The variability in column performance depending on sample type speaks to the complexity of these therapeutics and how each batch can behave differently.

  • PolyA Tail Significance: The polyA tail length is essential because it affects the stability of mRNA and its translational efficiency. Shorter or longer polyA tails can have significant consequences on the half-life of the mRNA and how well it is translated into protein. This type of analysis, as mentioned, is a great way to gain insights into the mRNA’s potential performance before it reaches clinical application.